Elisa Giovannetti
Elisa Giovannetti
Associate Professor - UHD
Email yang diverifikasi di vumc.nl
JudulDikutip olehTahun
Guidelines for the use and interpretation of assays for monitoring autophagy
DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ...
Autophagy 8 (4), 445-544, 2012
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ...
Cancer research 70 (11), 4528-4538, 2010
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti, M Del Tacca, V Mey, N Funel, S Nannizzi, S Ricci, ...
Cancer research 66 (7), 3928-3935, 2006
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer
JH Hwang, J Voortman, E Giovannetti, SM Steinberg, LG Leon, YT Kim, ...
PloS one 5 (5), e10630, 2010
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan, S Nannizzi, ...
Clinical Cancer Research 14 (6), 1797-1803, 2008
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells
E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, L Marini, M Del Tacca, ...
Molecular pharmacology 68 (1), 110-118, 2005
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells
C Granchi, S Roy, C Giacomelli, M Macchia, T Tuccinardi, A Martinelli, ...
Journal of medicinal chemistry 54 (6), 1599-1612, 2011
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolateá…
E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi, JA Rodriguez, ...
Molecular pharmacology 73 (4), 1290-1300, 2008
Analysis of drug interactions
IV Bijnsdorp, E Giovannetti, GJ Peters
Cancer Cell Culture, 421-434, 2011
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
F Broekman, E Giovannetti, GJ Peters
World journal of clinical oncology 2 (2), 80, 2011
MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression
AE Frampton, L Castellano, T Colombo, E Giovannetti, J Krell, J Jacob, ...
Gastroenterology 146 (1), 268-277. e18, 2014
Platinum-induced neurotoxicity and preventive strategies: past, present, and future
A Avan, TJ Postma, C Ceresa, A Avan, G Cavaletti, E Giovannetti, ...
The oncologist 20 (4), 411-432, 2015
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
E Giovannetti, A Erozenci, J Smit, R Danesi, GJ Peters
Critical reviews in oncology/hematology 81 (2), 103-122, 2012
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
PA Zucali, MG Ruiz, E Giovannetti, A Destro, M Varella-Garcia, K Floor, ...
Annals of Oncology 19 (9), 1605-1612, 2008
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines
E Giovannetti, V Mey, R Danesi, I Mosca, M Del Tacca
Clinical cancer research 10 (9), 2936-2943, 2004
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer
E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, M Del Tacca, R Danesi
Molecular Cancer Therapeutics 5 (6), 1387-1395, 2006
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancerá…
L De Mattos-Arruda, G Bottai, PG Nuciforo, L Di Tommaso, E Giovannetti, ...
Oncotarget 6 (35), 37269, 2015
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, EF Smit, ...
Journal of Chromatography B 878 (15-16), 1059-1068, 2010
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
PA Zucali, E Giovannetti, A Destro, M Mencoboni, GL Ceresoli, ...
Clinical Cancer Research 17 (8), 2581-2590, 2011
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non–small cell lung cancer
JSW Lind, AMC Dingemans, HJM Groen, FB Thunnissen, O Bekers, ...
Clinical Cancer Research 16 (11), 3078-3087, 2010
Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.
Artikel 1–20